OSTPRE-Fracture Prevention Study (OSTPRE-FPS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the effect of calcium 1000 mg/d and vitamin-D3 800 IU/d divided in two daily doses on the incidence of falls and fractures, bone mineral density and bone metabolism in postmenopausal women 65-71 years of age.
| Condition | Intervention | Phase |
|---|---|---|
|
Fractures Osteoporosis |
Dietary Supplement: calcium carbonate and cholecalciferol |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study |
- fractures [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
- falls [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
- bone mineral density measured by axial DXA, heel pDXA, heel QUS and distal forearm pQCT [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
- markers of bone metabolism [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
- serum vitamin-D levels [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
- serum calcium levels [ Time Frame: 3 year follow-up ] [ Designated as safety issue: No ]
| Enrollment: | 3432 |
| Study Start Date: | August 2002 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Ia
1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
|
Dietary Supplement: calcium carbonate and cholecalciferol
one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
Other Name: Calcichew D3 forte (Leiras-Nycomed), ATC-code: A12AX
|
|
Active Comparator: Ib
random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
|
Dietary Supplement: calcium carbonate and cholecalciferol
one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
Other Name: Calcichew D3 forte (Leiras-Nycomed), ATC-code: A12AX
|
|
No Intervention: IIa
1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
|
|
|
No Intervention: IIb
random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
|
Detailed Description:
In aging population osteoporotic fractures in postmenopausal women are a growing problem and a cause of remarkable morbidity, individual suffering and costs. The effect of calcium and vitamin-D in fracture prevention have been tested in elderly patients mostly over 70-75 years of age and results with low dose intervention have been controversial. The aim of this study is to determine the effects of calcium (1000 mg/d) and vitamin-D (800 IU/d) in 65-71 year-old postmenopausal women in a clinical trial on two levels: a) a randomized postal interview trial (n=3432) and b) a randomized clinical trial (n=606). 5407 women of the OSTPRE-cohort received a postal enquiry with questions of health related issues and willingness to participate a calcium and vitamin-D survey. 4706 enquiries were returned. 3432 eligible women were randomised to the active treatment group (n=1718) to receive the intervention and control group (n=1714), that did not receive placebo, they were told to go on as before in terms of calcium or vitamin-D substitution. On the level of the interview trial end point variables, falls and fractures, are collected by telephone interviews annually and on the level of the clinical trial every four months. In clinically examined subset of 606 subjects axial and heel bone mineral density (BMD), heel quantitative ultrasound (QUS) measurement, anthropometric measurements, a comprehensive set of clinical (muscle strength, balance, functional capacity) and laboratory tests (serum calcium, phosphate, AFOS, creatinine, cholesterol, triglycerides, complete blood count, 25-OH-D-vitamin, PTH, osteocalcin and Trap5B and reserve, serum and urine samples) will be performed and food diary will be obtained at baseline and after 3 years follow-up and baseline blood samples will be taken for DNA-analyses.
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Alive member of the original population based sample (n=14220) of Kuopio Osteoporosis Risk factor and Prevention Study
- Age 65 years or older on 30.11.2002
- Not participating any previous BMD-measurement in OSTPRE
- Living in the province of Kuopio
- Adequately filled baseline enquiry
- Willing to participate calcium and vitamin-D -survey
Contacts and Locations| Finland | |
| Bone and Cartilage Research Unit, Clinical Research Centre, University of Kuopio | |
| Kuopio, Finland, 70211 | |
| Study Chair: | Heikki P Kroger, Professor | Department of Orthopedics, Traumatology and Hand Surgery, University Hospital of Kuopio |
| Study Director: | Heikki P Kroger, Professor | Department of Orthopedics, Traumatology and Hand Surgery, University Hospital of Kuopio |
| Principal Investigator: | Marjo Tuppurainen, Professor | Department of Gynecology and Obstetrics, University Hospital of Kuopio |
More Information
No publications provided by Kuopio University Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Professor Heikki Kroger, Kuopio University Hospital, Dept of Orthopedics, Traumatology and Handsurgery |
| ClinicalTrials.gov Identifier: | NCT00592917 History of Changes |
| Other Study ID Numbers: | KUH5204512, 119/2001 |
| Study First Received: | January 2, 2008 |
| Last Updated: | January 11, 2008 |
| Health Authority: | Research Ethics Committee, Hospital District of Northern Savo, Finland: |
Keywords provided by Kuopio University Hospital:
|
osteoporosis fractures risk of fracture vitamin-D |
calcium falls bone mineral density bone metabolism |
Additional relevant MeSH terms:
|
Fractures, Bone Osteoporosis Wounds and Injuries Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Calcium, Dietary Cholecalciferol Vitamin D Ergocalciferols |
Calcium Carbonate Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Antacids Molecular Mechanisms of Pharmacological Action Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on June 17, 2013